Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 06/05/2026 | CALL | $1,150.00 | 2,040 | +761 | +59.50% |
| 07/10/2026 | PUT | $750.00 | 736 | +736 | |
| 06/26/2026 | CALL | $1,130.00 | 400 | +400 | |
| 06/26/2026 | PUT | $1,130.00 | 400 | +400 | |
| 07/10/2026 | PUT | $760.00 | 385 | +385 | |
| 06/12/2026 | CALL | $1,200.00 | 1,227 | +370 | +43.17% |
| 06/18/2026 | CALL | $1,300.00 | 963 | -189 | -16.41% |
| 06/12/2026 | CALL | $1,120.00 | 263 | -216 | -45.09% |
| 06/18/2026 | CALL | $1,200.00 | 2,606 | -258 | -9.01% |
| 06/05/2026 | PUT | $1,040.00 | 328 | -281 | -46.14% |
| 06/05/2026 | CALL | $1,130.00 | 719 | -422 | -36.99% |
| 06/05/2026 | CALL | $1,120.00 | 2,162 | -4,480 | -67.45% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
06/06 12:15 pm
The Motley Fool
Read moreNovo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
06/06 09:15 am
The Motley Fool
Read moreStock Market Today, June 4: Broadcom Drags on Nasdaq at Midday
06/04 12:39 pm
The Motley Fool
Read moreWeight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
06/04 12:17 pm
Benzinga
Read moreEli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
06/04 09:27 am
The Motley Fool
Read morePrediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years
06/03 01:17 pm
The Motley Fool
Read more1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
06/03 12:05 pm
The Motley Fool
Read moreState Street's Health Care ETF Tops Invesco's on Yield and Returns
06/02 07:10 am
The Motley Fool
Read moreEli Lilly Deepens Innovation Push Through New Biopharma Collaborations
06/01 01:19 pm
Benzinga
Read moreLilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
05/30 08:15 am
The Motley Fool
Read moreThe Smartest Growth Stocks to Buy With $2,000 Right Now
05/30 06:15 am
The Motley Fool
Read moreStock Market Today, May 28: Tech Stocks Rise as Snowflake Surges After $6 Billion Amazon Deal and Strong Earnings
05/28 02:06 pm
The Motley Fool
Read moreContrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
05/28 12:15 pm
The Motley Fool
Read moreVHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
05/28 08:07 am
The Motley Fool
Read moreTrogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
05/28 07:00 am
GlobeNewswire Inc.
Read more5 Undervalued Stocks You Can Buy and Hold Forever
05/28 04:15 am
The Motley Fool
Read morePresident Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
05/27 02:02 pm
The Motley Fool
Read moreGLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
05/27 11:17 am
The Motley Fool
Read moreTherini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
05/27 10:00 am
GlobeNewswire Inc.
Read moreMicron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next.
05/26 10:16 pm
The Motley Fool
Read moreIs Eli Lilly Stock an Undervalued Stock to Buy?
05/26 06:17 pm
The Motley Fool
Read moreInvestment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
05/26 02:29 pm
The Motley Fool
Read moreFrom Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave
05/26 01:38 pm
Benzinga
Read moreCurevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
05/26 06:45 am
Benzinga
Read morePrediction: These 2 Obesity Drug Stocks Could Double in 2026
05/26 04:04 am
The Motley Fool
Read moreChamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%
05/26 02:06 am
Benzinga
Read moreEli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
05/25 07:15 pm
The Motley Fool
Read moreEli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
05/25 05:05 am
The Motley Fool
Read moreIs Viking Therapeutics a Top Takeover Target?
05/23 04:31 pm
The Motley Fool
Read moreThe Most Important Healthcare Stock You're Not Watching
05/22 05:15 pm
The Motley Fool
Read moreEli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
05/21 02:24 pm
Benzinga
Read moreFrom Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
05/21 10:43 am
Investing.com
Read moreBest Weight Loss Drug Stocks to Buy in 2026
05/20 11:15 pm
The Motley Fool
Read moreESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
05/20 01:00 pm
GlobeNewswire Inc.
Read moreTrump's Stock Picks Perfectly Timed With New Medicare Rules: Report
05/19 01:37 pm
Benzinga
Read moreEli Lilly Stock: Next Stop $2,000?
05/18 06:30 pm
The Motley Fool
Read moreSupreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case
05/18 01:42 pm
Benzinga
Read moreSitryx to Participate in Upcoming Investor Conferences
05/18 07:00 am
GlobeNewswire Inc.
Read moreIs Kailera Therapeutics a Buy After Its Sizzling IPO?
05/16 10:30 am
The Motley Fool
Read moreMy Top 3 Healthcare Stocks for May 2026
05/15 08:33 am
The Motley Fool
Read moreOligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
05/14 01:00 pm
GlobeNewswire Inc.
Read moreWhy Doximity Stock Plunged Today
05/14 11:03 am
The Motley Fool
Read moreShould Eli Lilly Investors Worry About Its Newest Rival -- From Within?
05/14 05:05 am
The Motley Fool
Read moreIs Novo Nordisk's Rebound for Real--or Just a Head Fake?
05/13 01:15 pm
The Motley Fool
Read moreGlobal AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight
05/13 01:00 pm
GlobeNewswire Inc.
Read moreGlobal Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
05/13 01:00 pm
GlobeNewswire Inc.
Read moreEli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
05/13 11:33 am
Benzinga
Read moreFirst-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
05/13 07:00 am
GlobeNewswire Inc.
Read moreWhy Hims & Hers Health Stock Just Crashed
05/12 11:32 am
The Motley Fool
Read more